CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
Source: SeekingAlpha
2025-12-22 10:15:04 ET
Thesis Update
About a year ago, my first analysis of CareDx, Inc. ( CDNA ) was published. Against the grain of public opinion – almost every other analysis had a Hold or Buy rating – I rating it a “Sell,” due to several concerns I had. These were generally related to the following, which I’ll discuss in more detail later on:
- Profitability.
- Regulatory challenges.
- Competitive moat.
- Litigation issues.
- Management concerns and capital allocation.
Read the full article on Seeking Alpha
For further details see:
CareDX Has Reached An Inflection Point, But Regulatory Risks Remain (Upgrade)
Qiagen N.V.
NASDAQ: QGEN
QGEN Trading
-3.03% G/L:
$41.90 Last:
1,050,835 Volume:
$42.64 Open:
QGEN Latest News
March 10, 2026 05:05:00 pm
QIAGEN Receives U.S. Clearance for Gastrointestinal Panels on Fully Automated QIAstat-Dx Rise Syndromic Testing System
QGEN Stock Data
$10,633,318,293
203,932,295
N/A
22
N/A
Biotechnology & Life Sciences
Healthcare
NL
Venlo
